BioXcel Therapeutics, Inc. (BTAI): Price and Financial Metrics


BioXcel Therapeutics, Inc. (BTAI): $30.70

0.09 (+0.29%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BTAI Stock Price Chart Interactive Chart >

Price chart for BTAI

BTAI Price/Volume Stats

Current price $30.70 52-week high $67.74
Prev. close $30.61 52-week low $23.07
Day low $30.41 Volume 777,600
Day high $32.00 Avg. volume 437,802
50-day MA $26.97 Dividend yield N/A
200-day MA $38.53 Market Cap 858.65M

BioXcel Therapeutics, Inc. (BTAI) Company Bio


BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is based in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.


BTAI Latest News Stream


Event/Time News Detail
Loading, please wait...

BTAI Latest Social Stream


Loading social stream, please wait...

View Full BTAI Social Stream

Latest BTAI News From Around the Web

Below are the latest news stories about BioXcel Therapeutics Inc that investors may wish to consider to help them evaluate BTAI as an investment opportunity.

BTAI: Encouraging Data for BXCL701 in Heavily Pretreated mCRPC Patients…

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Encouraging Data for BXCL701 in Heavily Pretreated mCRPC Population On September 15, 2021, BioXcel Therapeutics, Inc. (BTAI) announced that data from the ongoing Phase 1b/2 clinical trial of BXCL701 in patients with metastatic castration-resistant prostate cancer (mCRPC) was presented at the 2021 European Society

Yahoo | September 17, 2021

BioXcel Therapeutics Presents Results from Ongoing Phase 2 Trial of BXCL701 in Combination with KEYTRUDA® in Aggressive Forms of Prostate Cancer at ESMO

BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging anti-tumor activity in heavily pre-treated mCRPC patients with adenocarcinoma BXCL701 combination continues to exhibit favorable safety profile; patient enrollment continues as per protocol NEW HAVEN, Conn., Sept. 15, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno

Yahoo | September 15, 2021

BioXcel Therapeutics to Present Updates from Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2021 ESMO Congress

NEW HAVEN, Conn., Sept. 12, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that updates from its ongoing Phase 1b/2 trial of BXCL701, the Company''s investigational, oral innate immunity activator, in aggressive forms of prostate cancer will be presented in a poster session at the 2021 European Society for Medical Oncology (ESMO) Congress, which will take place virtually from September 16-21, 2021.

Intrado Digital Media | September 12, 2021

BioXcel Therapeutics to Host Virtual R&D Day on September 23, 2021

Live webcast, Revolutionizing Drug Discovery and Development Through AI , to be held from 12:00 PM ET 2:00 PM ET

Intrado Digital Media | September 9, 2021

BTAI: PDUFA Date of Jan. 5, 2022 for BXCL501

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update PDUFA Date for BXCL501 of January 5, 2022; MAA Submission Expected 2H21 In May 2021, BioXcel Therapeutics, Inc. (NASDAQ:

Business Insider Markets | September 3, 2021

Read More 'BTAI' Stories Here

BTAI Price Returns

1-mo 26.49%
3-mo -16.69%
6-mo -23.97%
1-year -36.57%
3-year 307.16%
5-year N/A
YTD -33.55%
2020 216.22%
2019 278.50%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7858 seconds.